Brief: Regenxbio Announces FDA Acceptance And Priority Review Of BLA For Rgx-121 For Mps Ii
13/05/2025 12:40
May 13 (Reuters) - Regenxbio Inc RGNX.O: REGENXBIO ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF THE BLA FOR RGX-121 FOR MPS II REGENXBIO INC - FDA GRANTS PRIORITY REVIEW FOR RGX-121, ACTION DATE NOV 9, 2025 Source text: ID:nPn4lkvMxa Further company coverage: RGNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics